In a phase 3 trial, 123 patients with FLT3-ITD-positive AML who are not eligible for intensive chemotherapy were treated with gilteritinib plus azacitidine or azacitidine alone and CRc rates were 58.1% and 26.5% respectively showing no new significant safety issues compared to individual therapy (NCT02752035) [236••]. The gene discussed is FLT3; the disease is acute myeloid leukemia.